Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group
The presence of anaplastic lymphoma kinase (ALK) rearrangement defines a molecular subtype of non-small cell lung cancer (NSCLC). ALK inhibitors (ALKIs) confer significant clinical benefits in patients with ALK-positive advanced NSCLC; therefore, it is of great clinical significance to select accura...
Main Authors: | Wenbin Li, Jing Zhang, Zhijie Wang, Lin Li, Jie Ma, Xiaoyang Zhou, Jie Wang, Zhiyong Liang, Jianming Ying |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | Journal of the National Cancer Center |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S266700542100034X |
Similar Items
-
SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report
by: Lin Ma, et al.
Published: (2022-03-01) -
TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature
by: Andrew Xiao, et al.
Published: (2023-05-01) -
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01) -
Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
by: Xueqian Wu, et al.
Published: (2020-06-01) -
The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
by: Stephen P. Ducray, et al.
Published: (2019-07-01)